Wedbush reiterates Outperform rating on Aktis Oncology, $35 price target

Aktis Oncology (NASDAQ:AKTS) began a Phase 1b trial for AKY-2519 in lung cancer and other solid tumors. The multicenter study will test three dose levels. The company also has ongoing trials for prostate cancer and Nectin-4 expressing tumors, with data expected in 2027. Aktis develops targeted radioconjugates and collaborates with Eli Lilly.

Aktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing so

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

Amazon and Google signed 20-year deals with Constellation Energy for nuclear power, totaling $4.3B. Amazon secured 690 MW from Calvert Cliffs, while Google's deal covers 11 reactors. Critics question if these agreements will meet data center demand and impact household electricity costs. The Energy Department approved $4.4B in loans for nuclear facilities. Meta, Microsoft, and Amazon have also made significant nuclear power agreements.